国产紫杉醇与卡铂联合化疗晚期非小细胞肺癌的临床观察

Clinical Observation of Combined Chemotherapy of Domestic Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer

目的:评价国产紫杉醇对晚期非小细胞肺癌(NSCLC)的疗效。方法:37例晚期非小细胞肺癌应用国产紫杉醇135mg/m2,静脉滴注3小时,卡铂300～350mg/m2,静脉滴注,联合化疗,每4周为1个周期,共2～3个周期。结果:31例初治者有效率为35.5%,6例复治者有效率为33.3%,总有效率为35.1%,24例可评价的生存期病例中,中位生存期9.6个月,1年生存率33.3%,主要不良反应是骨髓抑制,脱发、恶心、呕吐,关节、肌肉痛,未见严重过敏反应。结论:国产紫杉醇是治疗晚期非小细胞肺癌的有效药物,安全且耐受。

Objective:To evaluate the efficacy of domestic paclitaxel on advanced non-small cell lung cancer(NSCLC).Methods:Thirty-seven patients with NSCLC were enrolled in this study.Domestic paclitaxel135mg /m 2 combined with carboplatin300～500mg /m 2 was given intravenously for three hours.Each regimen included2to3cycles and it was repeated every four weeks.Results:The response rate for31cases of de novo patients was35.5%and that of6relapsed cases was33.3%with a total response rate of35.1%.For24cases of evaluable cas-es,the medium survival time was9.6months and one-year survival rate was33%.The major side effects were myelosuppression,alopecia,nausea,vomiting,arthralgia and muscle pain.No severe sensitivity reaction was observed.Conclusion:Domestic paclitaxel is effective,safe and tolera ble antitumor agent in treatment of NSCLC.